AEFS.L Regulatory News (AEFS)

Alcentra European Floating Rate Income Fund Limited

Market Commentary

The European loan market in July returned to the strong performance seen for most of the year, with the Credit Suisse Western European Leveraged Loan Index ("CS WELLI") (hedged to EUR) posting a +0.48% return. This took the CS WELLI return for the year to date to +2.55%[1].

Supply over the month continued to be strong, with deals announced for a range of issuers including €1 billion+ deals for Techem, Diversey and Holland & Barrett. With July the second busiest month of the year, and second consecutive month with over €10 billion of issuance, the increase in loan supply has helped move the market to a better balance between buyers and sellers. With the secondary market more balanced and investors more discriminating in the primary market, there has been some increase in primary spreads from the levels seen earlier in the year.

Year-to-date loan volume stood at €70.4 billion at month-end, 87% up on 2016. As we have mentioned previously a significant proportion (61.2%) of this has been refinancing rather than new financings, although this has improved over recent months with only 40% of June/July volumes accounted for by refinancings. However, year-to-date new acquisition loan volume at €27.3 billion, remains only 4.3% above last year, despite €12.9 billion of supply in June/July (75.5% up over 2016)[2].

The post summer pipeline looks to be building, with large deals expected for Stada, Avavtor/VWR and Refresco/Cott, and the press also reporting that private equity manager are likely to bid for a range of larger assets including Paysafe, Akzo Nobel's specialty chemicals division, Unilever's spreads business, CPA Global, Nets and Teamviewer[3]. With demand for the asset class remaining robust this supply will be important in keeping the market balanced going into year-end.

Portfolio Update

The worst performer was again New Look (-7.0%) which continued to see the impact from weaker results leading to the selling of the FRN. Olive oil manufacturer Boparan was also down -4.6% with the weak olive oil harvest continuing to impact performance, while Oberthur declined -1.2% after a profit warning from its listed competitor Gemalto. The strongest performer was Vivarte's super senior debt (+10.4%) which recovered from recent weak performance, while two other names increased by just over 3%.

ENDS.

For further information please contact:

Alcentra Limited

Simon Perry +44 20 7367 5272

Factsheet

An accompanying factsheet which includes the information above as well as wider commentary on the investments made by the Fund can be found on the Fund's website www.aefrif.com.

Background Information

Alcentra European Floating Rate Income Fund Limited, a Guernsey Authorised Closed-Ended Collective Investment Scheme, regulated by the Guernsey Financial Services Commission and listed on the Main Market of the London Stock Exchange invests predominantly in senior secured loans and senior secured bonds issued by European corporates and targets returns (net of fees and expenses) of 7% to 10% per annum. The Fund targets a dividend yield of 5.5 pence per £1.00 issue price of the initial offering of shares in the Fund for the first full year of investment, paid quarterly.

Important Notices

Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

This report is aimed at existing investors in the fund and has not been approved by any competent regulatory authority.

The information contained in this document is given as at the date of its publication (unless otherwise marked) and is based on past performance. Past performance is not a guide to future performance and the value of investments and investment value can go down as well as up. The future performance of the Fund will depend on numerous factors which are subject to uncertainty. Including changes in market conditions and interest rates and exchange rates and in response to other economic, political or financial developments, investment return and principal value of your investment will fluctuate, so that when your investment is sold, the amount you receive could be less than what you originally invested. Past or current yields are not indicative of future yields.

This document does not contain any representations, does not constitute or form part of any solicitation of any offer to sell or invitation to purchase any securities of the Fund, nor shall it or any part of it or the fact of its distribution form the basis of or be relied upon in connection with any contract therefor, and does not constitute a recommendation regarding the securities of the Fund. Nothing in this document should be construed as a profit or dividend forecast.

This document includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements include, without limitation, statements typically containing words such as "believes", "considers", "intends", "expects", "anticipates", "targets", "estimates", "will", "may", or "should" and words of similar import. The forward-looking statements are based on the beliefs, assumptions and expectations of future performance and market development of Alcentra Limited ("Alcentra"), taking into account information currently available and made as at the date of this document. These can change as a result of many possible events or factors, not all of which are known or within Alcentra's control. If a change occurs, the Fund's business, financial condition, liquidity and results of operations may vary materially from those expressed in the forward-looking statements. By their nature, forward-looking statements involve known and unknown risks and uncertainties. Forward-looking statements are not guarantees of future performance. Alcentra qualifies any and all of the forward-looking statements by these cautionary factors. Please keep this cautionary note in mind while reading this document.

An investment in the Fund is suitable only for investors who are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear losses (which may equal the whole amount invested) that may result from such an investment. An investment in the Fund should constitute part of a diversified investment portfolio. Accordingly, typical investors in the Fund are expected to be sophisticated and/or professional investors who understand the risks involved in investing in the Fund.

Alcentra gives no undertaking to provide recipients of this document with access to any additional information, or to update this document or any additional information, or to correct any inaccuracies in it which may become apparent including in relation to any forward-looking statements. The distribution of this document shall not be deemed to be any form of commitment on the part of Alcentra to proceed with any transaction.

This document is issued by Alcentra Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority and whose registered address is at 160 Queen Victoria Street, London, United Kingdom, EC4V 4LA.

BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation and may also be used as a generic term to reference the Corporation as a whole or its various subsidiaries generally.

© 2017 The Bank of New York Mellon Corporation. All rights reserved. Trademarks and logos belong to their respective owners.